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Embedded pragmatic clinical trials (ePCTs) and quality improvement (QI) activities often occur simultaneously
within healthcare systems (HCSs). Embedded PCTs within HCSs are conducted to test interventions and provide
evidence that may impact public health, health system operations, and quality of care. They are larger and more
broadly generalizable than QI initiatives, and may generate what is considered high-quality evidence for po
tential use in care and clinical practice guidelines. QI initiatives often co-occur with ePCTs and address the same
high-impact health questions, and this co-occurrence may dilute or confound the ability to detect change as a
result of the ePCT intervention.
During the design, pilot, and conduct phases of the large-scale NIH Collaboratory Demonstration ePCTs, many
QI initiatives occurred at the same time within the HCSs. Although the challenges varied across the projects,
some common, generalizable strategies and solutions emerged, and we share these as case studies.
Key lessons: Study teams often need to monitor, adapt, and respond to QI during design and the course of the trial.
Routine collaboration between ePCT researchers and health systems stakeholders throughout the trial can help
ensure research and QI are optimally aligned to support high-quality patient-centered care.
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1. Background

4. Design

Many decisions made in healthcare are based on low-quality evi
dence from small or observational studies.1,2 Large-scale embedded
pragmatic clinical trials (ePCTs) are typically proposed when there is
sufficient evidence from these studies and enough uncertainty about the
effects and value of implementing an intervention in everyday clinical
settings. Embedding PCTs within healthcare systems (HCSs) can maxi
mize efficiencies of conducting trials, support the potential adoption of
promising results, help generate high-quality evidence about important
public health questions, integrate best practices within health systems,
and improve quality of care. Simultaneously within health systems,
ongoing quality improvement (QI) activities that implement
smaller-scale interventions also regularly emerge to address urgent
public health issues in real time. Both ePCTs and QI initiatives have the
potential to improve health outcomes and promote high-quality, cost-
effective healthcare. The primary difference is that QI activities are
designed to change local processes and practice to achieve accepted
standards of care, and ePCTs are designed to help determine the stan
dards of care.3 The development and implementation of QI activities
within health systems during the course of ePCTs is a major challenge to
their design, methods, and assigned treatments. Therefore, such activ
ities may threaten the ability to glean reliable, broadly generalizable
evidence from the ePCT.

4.1. Challenge: Many pragmatic trials take a long time to complete, and
for urgent public health questions, there will be important competing QI
activities
4.1.1. Case example: Pragmatic Trial of User-centered Clinical Decision
Support to Implement Emergency Department-initiated Buprenorphine for
Opioid Use Disorder (EMBED)
Because opioid use disorder is a national public health crisis and
progress against opioid-related morbidity and mortality is sorely
needed, the study team embraced QI activities at study sites as essential
(and inevitable). To ameliorate the potential confounding effects of
these QI activities with the ePCT, in the planning phase the study team
(1) changed the design from a stepped-wedge to a group-randomized
trial to shorten the duration of the trial, thereby decreasing the impact
on temporal trends from emerging QI activities, (2) balanced QI activ
ities across sites with constrained randomization, and (3) planned to
track specific QI initiatives by site to determine their effect on the pri
mary outcome. The study team felt that these pragmatic approaches
might increase the generalizability of the findings given the allowances
for real-world QI co-occurring with the trial.
5. Pilot phase
5.1. Challenge: Sites might adopt or modify the trial intervention before
an ePCT is complete based on promising groundwork accomplished during
the pilot phase

2. Organizational context
Since 2013, the National Institute of Health’s (NIH) Health Care
Systems Research Collaboratory (Collaboratory) has supported over 15
large-scale, multi-site ePCTs that are conducted in healthcare settings.
Collaboratory ePCTs are typically conducted over four years and use
system infrastructure, such as staff, space, and data from electronic
health records (EHR), to implement trials and ascertain endpoints.4
Important healthcare and public health questions addressed by Collab
oratory trials and described in this Case Report include hospital-based
infections, colorectal cancer screening, dialysis outcomes, alternatives
to opioid treatment for chronic pain, and multiple co-morbid condition
management, among others (Table 1). When developing the trials, study
teams made adjustments to their trial design to accommodate QI ac
tivities co-occurring in the health system. During the conduct of these
trials, study teams noted changes to both usual care control arms and
intervention arms as a result of temporal changes in practice, particu
larly those due to QI initiatives within the HCS. This article uses case
examples from the Collaboratory to illustrate challenges and provide
strategies for the pilot phase, design, recruitment, site selection,
conduct, and analysis phases of ePCTs.

5.1.1. Case examples: Pragmatic Trial of Population-based Programs to
Prevent Suicide Attempt (SPOT)
During the pilot phase of the trial, HCS leaders at one site began
developing tools and workflows to support the integration of mental
healthcare into routine primary care as part of a system-wide QI
initiative. These leaders adapted a version of the suicide risk assessment
tool the research team had used in the pilot phase for SPOT to monitor
patients assigned to the care management intervention arm of the trial.
At the same time, the leaders adapted the assessment tool to help ensure
primary care patients who screened positive for frequent suicidal idea
tion received appropriate follow-up care. After trial randomization had
begun, the study team collaborated with health system leaders and
shared experiences to improve integration of the assessment tool into
the EHR and standard primary care workflows. Patient-level randomi
zation planned at the time of grant submission provided protection
against temporal biases introduced by this QI initiative that may have
been introduced had the team chosen randomization at the provider or
clinic level (a common design for ePCTs).

3. Problems and solutions

5.1.2. Lumbar Imaging with Reporting of Epidemiology (LIRE)
During the pilot phase, one of the four HCSs independently imple
mented a QI intervention similar to the LIRE intervention (i.e., epide
miological benchmark text representing the normal range in imaging
reports) in the hopes of decreasing inappropriate spine care. After the
study team had discussions with local radiology leadership, the site
agreed to remove the text from their radiology reports so as not to
confound the trial. The stepped-wedge design of the trial facilitated the
discussions with site leadership as all of the participating clinics would
have the intervention text in the radiology reports by the trial’s
conclusion.

The Collaboratory ePCTs are in various phases—some are currently
being designed, launched, or conducted; some are in the data analysis
phase; and others have been completed. During the design, pilot, and
conduct phases of these trials, a multitude of QI initiatives created
different challenges across a number of the HCSs involved in the trials
(Fig. 1). The following examples describe the strategies and solutions
used to counter the challenges; from these examples, we further develop
common, generalizable strategies and recommendations for future
ePCTs.
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Table 1
Collaboratory ePCTs described in this Case Report*.
Trial

Goal

Healthcare Systems (HCSs)/
Patients

Trial Design

Phase and brief summary
of issue

Active Bathing to Eliminate
(ABATE) Infection study
(NCT02063867); Status:
complete

To reduce multidrug-resistant
organisms and bloodstream
infections compared to usual
care.5

53 HCA Healthcare hospitals (194
non-critical care units; ~340,000
patients in the intervention
period)

Conduct phase: potential
for competing
interventions

Guiding Good Choices for Health
(GGC4H) (NCT04040153);
Status: ongoing

To demonstrate the feasibility of
implementing Guiding Good
Choices in pediatric primary care
settings and evaluate its
effectiveness in reducing
adolescent substance use initiation
and improving behavioral health.

Three HCSs (Henry Ford Health
System, Kaiser Permanente
Colorado, Kaiser Permanente
Northern California; ~3600
families)

Improving Chronic Disease
Management with Pieces (ICDPieces) (NCT02587936); Status:
ongoing

To test the hypothesis that patients
with chronic kidney disease
(CKD), diabetes, and hypertension
who receive care with a
collaborative model of primary
care-subspecialty care enhanced
by novel information technology
(Pieces) and practice facilitators
will have fewer hospitalizations,
readmissions, cardiovascular
events and deaths than patients
receiving standard medical care.
To demonstrate that a simple and
inexpensive intervention,
providing what are essentially
normal values for diagnostic
imaging, would decrease health
care interventions such as
diagnostic testing, injections,
opioid prescriptions and
surgeries.6
To assess the potential benefit of
helping patients adopt selfmanagement skills for chronic
pain, limit use of opioid
medications, and identify factors
amenable to treatment in the
primary care setting in three
health systems.7
To improve medication refill
adherence among patients with
cardiovascular diseases (coronary
artery disease, diabetes,
hypertension, hyperlipidemia and
atrial fibrillation) vs usual care

Four HCSs (Parkland Health and
Hospital System, VA North Texas,
Texas Health Resources and
ProHealth Physicians;
~11,000 patients)

Cluster-randomized trial of daily
antiseptic bathing for all patients
and nasal antibiotic ointment for
patients harboring methicillinresistant Staphylococcus aureus
(MRSA) compared to routine care
Cluster-randomized trial with
randomization at the pediatrician
level; parents whose adolescents
are empaneled with intervention
arm pediatricians will be offered
Guiding Good Choices, a 5-session
evidence-based preventive
anticipatory guidance intervention
for parents of young adolescents.
Group randomized to receive ICDPieces, which is facilitated by
clinical decision support and
practice facilitators

Four HCSs (Kaiser Permanente
Northern California, Kaiser
Permanente Washington, Mayo
Clinic Health System, Henry Ford
Health System; 98 clinics;
~250,000 patients)

A stepped-wedge randomized trial
of inserting epidemiological
benchmark data in routine spine
imaging reports

Pilot phase: Launch of
similar intervention

Three Kaiser Permanente HCSs
(Northwest, Georgia, and Hawaii;
~800 patients)

Cluster randomized by primary
care provider to receive nonpharmacological interventions,
including physical therapy and
psychological interventions

Recruitment phase:
simultaneous QI efforts
caused confusion for
clinicians and potential
participants

Three HCSs (UCHealth, VA
Eastern Colorado Health Care
System, Denver Health; ~5000
patients)

Patient-level randomization to
usual care (no text message
reminders) vs generic text message
reminders, text message reminders
with behavioral nudges, or text
message reminders with behavioral
nudges and chatbot
Patient-level randomization to 1)
usual care 2) a care management
intervention or 3) an online skills
intervention

Conduct phase: many
similar concurrent QI
activities

Lumbar Imaging with Reporting of
Epidemiology (LIRE)
(NCT02015455); Status:
complete

Pain Program for Active Coping
and Training (PPACT) trial
(NCT02113592); Status:
complete

Personalized Patient Data and
Behavioral Nudges To Improve
Adherence to Chronic
Cardiovascular Medications
(Nudge) (NCT03973931);
Status: ongoing
Pragmatic Trial of Populationbased Programs to Prevent
Suicide Attempt (SPOT)
(NCT02326883); Status:
ongoing
Pragmatic Trial of User-Centered
Clinical Decision Support to
Implement EMergency
Department-Initiated
BuprenorphinE for Opioid Use
Disorder (EMBED)
(NCT03658642); Status:
ongoing
Primary Palliative Care for
Emergency Medicine (PRIM-ER)
(NCT03424109); Status:
ongoing

To evaluate the effectiveness of
two population-based outreach
programs for preventing suicide
attempts among patients
identified as at-risk.8
To increase rates of emergency
department-initiation of
Buprenorphine/naloxone and
referral for ongoing treatment for
patients with opioid-use disorder.
BUP is a well-established effective
treatment but its use has not been
routinely implemented into
emergency department care.9
To test the effectiveness of
primary palliative care education,
training, and technical support for
emergency medicine.10

Strategies and Opportunities to
STOP Colon Cancer in Priority
Populations (STOP CRC)

To determine whether EHRembedded tools and clinic staff
training in how to implement a

Conduct phase: potential
for exposure to similar
interventions

Conduct phase: Many
different overlapping
interventions

Four HCSs (HealthPartners and
Kaiser Permanente Washington,
Kaiser Permanente Colorado, and
Kaiser Permanente Northwest;
~19,000 patients)
20 Emergency Departments
across five HCSs ~9900 patients
(Yale New Haven Health,
University of North Carolina
Health University of AlabamaBirmingham Health, Baystate
Health, and University of
Colorado Health)

Pilot phase: Sites adapted a
version of the intervention
similar to one used in the
pilot phase

Group-randomized trial of usercentered computerized clinical
decision support

Design phase: potential for
confounding effects due to
multiple QI initiatives to
address opioid use disorder

35 emergency departments (EDs)
in 18 HCSs ranging from
academic medical centers to
community hospitals (~4983
providers; ~57,717 patients)
26 Federally Qualified Health
Centers (FQHCs) in 2 states

Stepped-wedge randomization to
asynchronous learning and
technical support to bolster
emergency providers’ palliative
care skills.
Group randomized to mailed fecal
immunochemical tests (FIT)

Site selection phase:
enrollment of early
adopters of innovations
may lead to multiple
competing interventions
Site selection phase: mix of
early and late adopting
(continued on next page)
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Table 1 (continued )
Trial
(NCT01742065); Status:
complete

Time to Reduce Mortality in EndStage Renal Disease trial (TiME)
(NCT02019225); Status:
complete

Goal

Healthcare Systems (HCSs)/
Patients

Trial Design

Phase and brief summary
of issue

mailed FIT outreach program
could increase colorectal cancer
screening uptake among patients
with historically lower CRC
screening rates and worse CRC
outcomes, such as those with low
income, or who are on Medicaid or
underinsured.11
To determine whether treatment
with hemodialysis sessions that
are longer than many patients in
the US currently receive reduces
the high rate of mortality among
people being treated with thriceweekly maintenance
hemodialysis.12

(Oregon and California, ~41,000
patients)

outreach and use of a real-time
EHR embedded tool

sites led to distinct
differences in sites

Two large US dialysis provider
organizations (DaVita, Inc.,
Fresenius Medical Care – North
America; 266 outpatient dialysis
facilities, 7035 patients)

Cluster randomization to a default
hemodialysis session duration of at
least 4.25 hours or to usual care (no
trial-driven approach to
hemodialysis session durations)

Site selection phase:
enrollment of late adopters
was associated with
inadequate
implementation of the
intervention

facility selection, it was apparent that hemodialysis session durations
were already increasing at many facilities operated by the dialysis pro
vider organizations, likely in response to observational studies demon
strating associations between longer session durations and improved
patient survival. Because this practice change was expected to decrease
the difference in session durations between the intervention and usual
care facilities, the study team decided to restrict enrollment to “lateadopter” facilities that had not already implemented longer session
durations. While this approach addressed one problem, it had the un
intended effect of enriching the trial for facilities that had less enthu
siasm to change to practice in the absence of rigorous evidence of
benefit, and thus, less willingness to broadly adopt the TiME interven
tion as routine care during the conduct of the trial.

6. Recruitment of participants
6.1. Challenge: QI activities during recruitment of an ePCT can create
confusion among participants and clinicians
6.1.1. Case example: Pain Program for Active Coping and Training (PP
ACT)
The study team needed to be aware of, coordinate, and measure QI
activities that included both 1) opioid therapy tapering- and safe userelated QI efforts, which did not directly compete with their interven
tion, and 2) nonpharmaco-therapy for chronic pain as an alternative for
opioids, which did directly compete with the intervention. However, the
simultaneous QI efforts that appeared similar to the PPACT intervention
caused unexpected confusion for both frontline clinicians and potential
participants who were concerned that their chronic opioid treatment
might be reduced or eliminated. To counter this, at one of the partici
pating HCSs, the investigators intensified orientation efforts to ensure
that potential participants fully understood their care options and how
the trial offerings fit into the broader array of pain-related services in the
healthcare system.

7.1.3. Strategies and Opportunities to Stop Colon Cancer in Priority
Populations (STOP CRC; enrolled mix of early and late adopters)
Whether or not a Federally Qualified Health Center (FQHC) was an
early or late adopter to innovations in care was not part of STOP CRC’s
selection criteria, although there were distinct differences between the
FQHCs. For example, some clinics assigned to usual care did not want to
wait to start the intervention because waiting raised some ethical and
participatory issues (not wanting to offer differing care across clinics in
their centers), so they were more likely to give out FIT kits at routine
clinic visits than they might have been had they not been part of the
study. Conversely, some sites in the intervention arm were slow to mail
the FIT kits. Implementation success varied across intervention clinics,
ranging from 21% to 82%, in lagged data. Although STOP CRC enrolled
a mix of early and late adopter FQHCs—which had the effect of diluting
the ability to detect changes due to the STOP CRC intervention, thereby
decreasing the overall intervention effectiveness—the active interven
tion was still significantly more effective than usual care. In the per
protocol analysis, intervention effect was similar to smaller trials
implemented in research settings, highlighting the need to carefully
design the analysis plan up front to account for these differences.

7. Site selection
7.1. Challenge: Health systems that are early adopters of evidence are
quick to change practice and have many QI activities. Late adopters may
be slow to implement evidence into care and to implement research
interventions
7.1.1. Case examples: Primary Palliative Care for Emergency Medicine
(PRIM-ER; enrolled early adopters)
The research team targeted collaboration with early adopter emer
gency departments that were beginning to prioritize palliative care
initiatives and had physician and nurse champions. While including
motivated sites helps with implementing a complex intervention, these
will likely be implementing other related programs, which may in turn
impact the same outcomes of the trial. The research team designed an
analysis plan that will account for this. Specifically, they will monitor QI
initiatives at the site level and plan to negotiate with clinical leadership
to delay or replace palliative initiatives with PRIM-ER activities.
Through ongoing tracking, the goal is to support and encourage local QI
while ensuring the outcomes of the trial are a result of the intervention
and not parallel programs.

8. Conduct and analysis
8.1. Challenge: different health systems participating in the same ePCT
could have varied implementation of both QI activities and the intervention
during the conduct of the trial
8.1.1. Case example: Improving Chronic Disease Management with Pieces
(ICD-Pieces)
All the participating health systems conducted different QI initiatives
that overlapped with key components of ICD-Pieces, including the
intervention, and could potentially affect the conduct and analysis of the
trial. For example, one health system has implemented initiatives to

7.1.2. Time to Reduce Mortality in End-stage Renal Disease Trial (TiME;
enrolled late adopters)
The TiME trial set out to test a longer dialysis session duration (4.25
hours) versus usual care (non-trial directed session duration). During
4
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promote better blood pressure control and measurement of Hemoglobin
AIc. Another has patient-facing education materials for CKD. A third
health system has eGFR prompts to trigger further consideration for
blood pressure and lipid control medication use. The fourth system
aligned provider incentives with best care practices for diabetes control.
The study team continues to monitor the QI activities at each HCS for
possible conflict or influence with ICD-Pieces in the intervention and
control groups.

8.2.2. Guiding Good Choices for Health (GGC4H)
With increasing integration of behavioral healthcare in pediatric
primary care settings, parents and adolescents may be exposed during
the 4-year GGC4H ePCT to parenting and behavioral health in
terventions other than Guiding Good Choices (GGC), implemented as
part of QI initiatives. These initiatives are unlikely to be offered uni
formly across clinics whether or not in the intervention or control arms,
raising the possibility that GGC’s impact will be dampened, confounded,
or both. The study team has developed several mechanisms to deal with
this possibility. First, the team has adopted a theoretical frameworkdriven implementation monitoring system to record QI initiatives and
other external and internal activities that could potentially impact GGC,
as they occur throughout the trial. Data collected prospectively will help
researchers identify and respond to challenges that arise and interpret
findings at the end of the trial. Second, the adolescent behavioral health
survey, administered to adolescents annually, will include questions
about other behavioral health service utilization. Third, the study team
includes pediatricians and embedded research teams with strong
working relationships and regular communication with clinic, pediat
rics, and adolescent medicine leaders. These relationships can be
leveraged to understand QI activities and their motivation, and, though
less likely, to influence QI implementation to avoid negative impacts on
ePCT results.

8.2. Challenge: Competing QI initiatives may impact the ability to
measure the primary outcome
8.2.1. Case examples: Active Bathing to Eliminate (ABATE) Infection study
Because hospitals routinely implement new QI interventions and
infection prevention is often a target of these QI strategies, the study
team needed to have a process for monitoring and addressing potential
conflicting QI initiatives that participating hospitals might pursue dur
ing the ePCT. As a requirement of participation in ABATE, infection
prevention strategies were required to be stable in the baseline year
preceding the trial and during the intervention period. Hospitals in both
arms were required to report any new QI or other interventions that
were being considered or launched during the trial. Reminders for
reporting were provided during monthly coaching calls, and early
reporting was encouraged when QI strategies were in the planning stage.
All reported QI initiatives were assessed weekly by the trial’s Steering
Committee. Hospitals that reported a competing intervention based
upon the Steering Committee’s concern for a meaningful effect that
could conflict with trial outcomes were asked to delay the QI initiatives
until the trial was over, or to drop from the trial. During the 21-month
trial, 196 QI interventions were reported to the Steering Committee,
with 67 (34%) deemed to directly compete with trial outcomes. Three
sites dropped from the trial (two in the control group and one in the
intervention group) to pursue a competing intervention. Data from these
sites were included in the as-randomized trial analysis, but were
removed from the as-treated analysis from the time of drop-out.

8.2.3. Personalized Patient Data and Behavioral Nudges to Improve
Adherence to Chronic Cardiovascular Medications (Nudge)
Nudge will provide text message reminders for patients with chronic
cardiovascular disease to refill their medications. Concurrent with the
study, two of the health systems implemented a medication adherence
tool within the EHR where clinicians can see the refill adherence of
patients. In addition, at some retail pharmacies where patients fill their
medications, there are existing text message reminders sent to patients.
The study is monitoring these concurrent QI processes, which should be
considered co-interventions. In the analysis, the study team will
consider these patients as an important subgroup in the assessment of
the effect of the intervention. They will be able to determine whether

Fig. 1. Challenges that arose from QI activities by phase of the ePCT.
5
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patients exclusively obtain their medications within the health system
pharmacy and/or through retail pharmacies. The study team also plans
to assess the effect of the intervention overall as well as within the
subgroup of patients who obtain medications via retail pharmacies.

3.

8.3. Unresolved questions and lessons from the field: recommendations
for researchers and QI and health system stakeholders
Researchers conducting ePCTs within HCSs have an ethical obliga
tion to give patients the best care possible, and one way to ensure that
care is evidence-based and high quality is to test interventions through
an ePCT. This evidence can be used to drive broad improvements across
many HCSs, change reimbursement policies, or introduce legislation to
help improve the care on a population level. Many QI activities,
although they tend to be smaller in scale, generally have the same goals
as ePCTs. However, some QI activities may, as described above, impact
an ePCT (Fig. 1): they may create confusion among participating pa
tients, clinicians and staff; be implemented differently (or not at all)
across the various systems; impact health systems differently depending
on local workflows and priorities; directly compete with the conduct of
the trial and intervention fidelity; increase demands on patients, staff,
and resources; sway general opinion; and potentially confound the re
sults of a trial. Solutions to challenges created by QI activities will vary
depending on the nature of the trial, challenges, and health systems in
which the trials are conducted.
It is important for the researcher to understand that HCS participa
tion in ePCTs is voluntary, and “ongoing commitment, shared vision, a
willingness to understand and accommodate different priorities” is
critical.13 Leaders of HCS participate for a variety of reasons, including
that evidence generation is for the greater good, research is in keeping
with the mission of the HCS, as a market differentiator, as part of per
formance improvement initiatives, and to gain early access to new
knowledge and best practices.14 Based on experiences of these ePCTs,
PIs, HCS leaders, and other members of the Collaboratory have devel
oped these recommendations to provide future researchers with a
roadmap to overcoming the challenges with co-occurring QI initiatives
during an ePCT, and for ensuring optimal patient care while preserving
the ability to answer important health questions.

4.

5.

1. Collaborate with HCS stakeholders in the design stage of the trial and
in the decision-making process. Continue this involvement through
each phase of the research to ensure synergy and, where possible,
minimize competing interventions that might confound the analysis
or contaminate the results. In addition, understanding the landscape
of concomitant competing interventions may be an important part of
understanding the context of trial findings. Understanding the
interaction between QI activities and implementation strategies
provides guidance for selection of effective strategies to test in realworld settings.
2. Understand the factors that motivate HCSs to undertake QI activities.
A map may be helpful to illustrate relationships among involved
health system leaders, their motivations, and the multiple internal
and external factors that are associated with the motivators, such as
changing policy, changing payor requirements, and other possible
constraints and considerations. There are formal ways of developing
relationship maps, such as mapping decision makers and influencers
or force field analyses used in the social sciences.15 Frameworks such
as the Consolidated Framework for Implementation Research (CFIR)
can also be useful in mapping the program/intervention to be eval
uated, and individual, internal, and external drivers and bar
riers.16,17 As an example, policy changes that incentivize health
plans or clinics to achieve targets could motivate new QI activities
and cause health system leaders to be reluctant to deliver inconsis
tent care across their clinics. Thus, they may introduce alternative QI
initiatives across usual care sites so all sites are similar. As another
example, in the case of FQHCs, a QI activity might be directly linked

6.

7.

to the funding stream that established QI priorities. If researchers
understand the genesis of potential tensions, they will be better able
to find a solution that meets the priorities of the HCS without
compromising the outcomes of the ePCT.
When ePCTs are embedded in HCSs where QI initiatives are com
mon, trial investigators should establish a reporting and monitoring
system to identify and address conflicting interventions. Systematic
monitoring of all influences that could affect the implementation of
an intervention include relevant health system QI initiatives, orga
nizational changes, as well as policy changes and environmental
factors that could affect adoption and implementation of the inter
vention. This is best accomplished by partnering with personnel
responsible for local QI initiatives and health system leaders and by
collaborating to develop a mechanism for reporting the potentially
competing initiatives. Knowledge of and response to conflicting in
terventions is critical to ensure that the interpretation of trial results
is valid. The possibility that sites may need to drop out of the trial due
to competing interventions should be accounted for in trial power
calculations, and potential biases introduced by such drop-out
should be considered.
HCS stakeholders may need to be asked to delay implementing a
competing QI initiative during an ongoing trial. As mentioned above,
a strong durable partnership based on trust, ongoing commitment,
and continuous communication is critical for this type of conversa
tion. QI activities are typically initiated to address a need, and
therefore, examining how (and if) the results of the ePCT will address
this need both locally and in a broader more generalizable context
are important aspects of the ongoing conversation. The success of
requests to delay QI activities will be related to the importance of the
ePCT question to participating sites and HCS leaders. Before making
a request, researchers should consider whether the competing
initiative is considered best-practice by national standards, as na
tionally accepted changes to best practice may need to be equally
implemented across all participating arms during the course of the
trial. The trial investigators should ensure equal opportunity and
encouragement for such changes; training can be implemented to
ensure the activities are implemented equally across all sites.
Ensure that statistical experts involved with the analyses are aware
of QI initiatives (or plans for initiatives), so they can recommend
appropriate actions and ideally, protect the validity of ePCT results.
For example, investigators could consider ways to shorten the
timeline both during the trial planning and trial conduct phases (e.g.,
stepped-wedge vs grouped cluster designs; larger sample size vs
longer follow-up for outcome event accrual) in case systems are
motivated to implement either a competing QI activity and/or the
research intervention across the HCS.
Developing clear communication between the study team and the
staff implementing the ePCT intervention before, during, and after
implementation within the HCS is critical to success. This includes
communicating results in a user-friendly way that can be used by
health system stakeholders to make decisions about intervention
adoption.
Assess the value of the ePCT intervention in the midst of all other QI
initiatives and demands on the provider and HCS. This “value” can
be considered through the lens of multiple stakeholders, including
patients (improved care and outcomes), clinicians (streamlined
workflow and processes), and healthcare systems (higher quality
care and lower costs). Adoption will more likely occur if the inter
vention is relevant to multiple stakeholders, such as an improvement
that will save the provider time, be patient-centered, and decrease
overall costs for the HCS.

9. Conclusions
Health systems are complex, dynamic and constantly evolving. QI
implementation within HCSs will continue and, therefore, continue to
6

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on July 20, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

L. Tuzzio et al.

Healthcare 8 (2021) 100432

be a challenge for conducting ePCTs within HCSs. Elucidating an
experimental effect in an ePCT can be challenging even without cooccurring or competing QI initiatives. In general, because the in
terventions in pragmatic trials are designed for heterogenous settings
that change over time, QI activities might lead to a dilution of the po
tential impact of the intervention. This might make it more likely that a
pragmatic trial will have a negative, diminished, or inconclusive result
compared with an explanatory trial. This happened in several of the NIH
Collaboratory trials.
Although there is an ethical imperative to protect the integrity of the
trial for the development of much needed evidence, there is also a pri
mary obligation to protect the well-being of participants and provide
high-quality care.18 For ePCTs to be rigorous, study teams must monitor,
adapt, and respond to QI during the design and the trial implementation.
Both ePCTs and QI happen within the same context and aim to improve
patient care, they are inherently interconnected. Indeed, the distinction
between QI activities and ePCTs is arguably fuzzy.19 As we transition
from a construct where research is conducted separately from healthcare
to one where research is a part of continuous learning, as in a learning
healthcare system,20 we expect to find more synergy between QI and
research and more robust partnerships and collaboration among those
responsible for QI, healthcare, and research. Therefore, routine collab
oration between ePCT researchers and HCS stakeholders are critically
important for optimally aligning research with QI to support
high-quality patient-centered care. Ideally, ePCTs should adapt to best
practice changes so that the comparator is always compared to best
practice (e.g., preventing out-of-date results at publication). Therefore,
in addition to avoiding unnecessary conflicting QI interventions, ePCTs
also need to embrace best practice change so that the trial intervention is
implemented against a background or comparator of best practice.

This manuscript has not been submitted to, nor is under review at,
another journal or other publishing venue.
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